Skip to Content

Tegaserod Disease Interactions

There are 4 disease interactions with tegaserod:

Major

Tegaserod (Includes tegaserod) ↔ intestinal obstruction

Severe Potential Hazard, High plausibility. Applies to: Intestinal Obstruction, Abdominal Adhesions, Gallbladder Disease

The use of tegaserod is contraindicated in patients with a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions. Stimulation of gastrointestinal motility might be harmful in these conditions.

References

  1. "Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals, East Hanover, NJ.
Major

Tegaserod (Includes tegaserod) ↔ liver disease

Severe Potential Hazard, High plausibility. Applies to: Liver Disease

The use of tegaserod is contraindicated in patients with moderate or severe hepatic impairment, as it has not been adequately studied for treatment in this population. In subjects with mild hepatic impairment, mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tegaserod were 16% and 31% higher, respectively, compared to subjects with normal hepatic function. No dosage adjustment is required in patients with mild hepatic impairment; however, caution is advised when using tegaserod in such patients.

References

  1. "Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals, East Hanover, NJ.
Major

Tegaserod (Includes tegaserod) ↔ renal dysfunction

Severe Potential Hazard, High plausibility. Applies to: Renal Dysfunction

The use of tegaserod is contraindicated in patients with severely impaired renal function. According to the manufacturer, no change in the pharmacokinetics of tegaserod was observed in subjects with severe renal impairment requiring hemodialysis (CrCl < 15 mL/min/1.73 m2). However, the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of the main pharmacologically inactive metabolite of tegaserod increased 2- and 10-fold, respectively, compared to healthy controls. The clinical significance of this observation is unknown. No dosage adjustment is required in patients with mild to moderate renal impairment.

References

  1. "Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals, East Hanover, NJ.
Moderate

Tegaserod (Includes tegaserod) ↔ diarrhea

Moderate Potential Hazard, High plausibility. Applies to: Diarrhea

Tegaserod should not be initiated in patients who are experiencing or frequently experience diarrhea. Tegaserod stimulates gastrointestinal motility and may cause diarrhea, usually within the first week of treatment. Patients should contact their physician if they experience severe diarrhea during therapy, or if the diarrhea is accompanied by severe cramping, abdominal pain, or dizziness.

References

  1. "Product Information. Zelnorm (tegaserod)." Novartis Pharmaceuticals, East Hanover, NJ.

Tegaserod drug interactions

There are 14 drug interactions with tegaserod

Tegaserod alcohol/food interactions

There is 1 alcohol/food interaction with tegaserod

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide